305 related articles for article (PubMed ID: 30926668)
21. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice.
Leinhase I; Rozanski M; Harhausen D; Thurman JM; Schmidt OI; Hossini AM; Taha ME; Rittirsch D; Ward PA; Holers VM; Ertel W; Stahel PF
J Neuroinflammation; 2007 May; 4():13. PubMed ID: 17474994
[TBL] [Abstract][Full Text] [Related]
23. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
24. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
25. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
Merrill SA; Brodsky RA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
[TBL] [Abstract][Full Text] [Related]
26. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
27. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships for substrate-based inhibitors of human complement factor B.
Ruiz-Gómez G; Lim J; Halili MA; Le GT; Madala PK; Abbenante G; Fairlie DP
J Med Chem; 2009 Oct; 52(19):6042-52. PubMed ID: 19743866
[TBL] [Abstract][Full Text] [Related]
29. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing antichlamydial activity of complement by chlamydia-secreted protease CPAF.
Yang Z; Tang L; Zhou Z; Zhong G
Microbes Infect; 2016 Nov; 18(11):669-674. PubMed ID: 27436813
[TBL] [Abstract][Full Text] [Related]
31. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.
Gullipalli D; Zhang F; Sato S; Ueda Y; Kimura Y; Golla M; Miwa T; Wang J; Song WC
J Immunol; 2018 Aug; 201(3):1021-1029. PubMed ID: 29898960
[TBL] [Abstract][Full Text] [Related]
32. Is generation of C3(H
Ekdahl KN; Mohlin C; Adler A; Åman A; Manivel VA; Sandholm K; Huber-Lang M; Fromell K; Nilsson B
Mol Immunol; 2019 Oct; 114():353-361. PubMed ID: 31446306
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
34. Regulation of the alternative pathway of complement by pH.
Fishelson Z; Horstmann RD; Müller-Eberhard HJ
J Immunol; 1987 May; 138(10):3392-5. PubMed ID: 2952717
[TBL] [Abstract][Full Text] [Related]
35. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H.
Bora NS; Kaliappan S; Jha P; Xu Q; Sohn JH; Dhaulakhandi DB; Kaplan HJ; Bora PS
J Immunol; 2006 Aug; 177(3):1872-8. PubMed ID: 16849499
[TBL] [Abstract][Full Text] [Related]
36. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome.
Cook HT
Curr Opin Nephrol Hypertens; 2018 May; 27(3):165-170. PubMed ID: 29517501
[TBL] [Abstract][Full Text] [Related]
37. Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.
Zhang W; Wu M; Vadlakonda S; Juarez L; Cheng X; Muppa S; Chintareddy V; Vogeti L; Kellogg-Yelder D; Williams J; Polach K; Chen X; Raman K; Babu YS; Kotian P
Bioorg Med Chem; 2022 Nov; 74():117034. PubMed ID: 36272185
[TBL] [Abstract][Full Text] [Related]
38. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy.
Lenderink AM; Liegel K; Ljubanović D; Coleman KE; Gilkeson GS; Holers VM; Thurman JM
Am J Physiol Renal Physiol; 2007 Aug; 293(2):F555-64. PubMed ID: 17522263
[TBL] [Abstract][Full Text] [Related]
39. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Ueda Y; Miwa T; Gullipalli D; Sato S; Ito D; Kim H; Palmer M; Song WC
J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
[No Abstract] [Full Text] [Related]
40. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
